Amarin (AMRN)
(Delayed Data from NSDQ)
$0.59 USD
-0.01 (-1.80%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $0.60 +0.01 (1.16%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.59 USD
-0.01 (-1.80%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $0.60 +0.01 (1.16%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth F Momentum C VGM
Zacks News
3 Biotech Stocks Likely to Maintain Solid Momentum in 2020
by Ekta Bagri
With the biotech sector gaining steam in recent times, we shortlist three biotech stocks that are set to maintain momentum in 2020.
Has Amarin Corporation (AMRN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMRN) Outperforming Other Medical Stocks This Year?
Amarin (AMRN) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Amarin (AMRN) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More
by Zacks Equity Research
The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.
Amarin Gains on FDA Approval of Vascepa Label Expansion
by Zacks Equity Research
Amarin (AMRN) gains as FDA approves a label expansion of Vascepa to reduce cardiovascular risk.
Is Amarin Corporation (AMRN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMRN) Outperforming Other Medical Stocks This Year?
Amarin (AMRN) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Amarin (AMRN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU
by Zacks Equity Research
The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.
Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for November 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 27th.
Amarin's Shares Down on Underperform Rating by Oppenheimer
by Zacks Equity Research
Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.
Will Amarin Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amarin.
Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion
by Zacks Equity Research
Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
What Makes Amarin (AMRN) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Amarin (AMRN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Has Amarin Corporation (AMRN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMRN) Outperforming Other Medical Stocks This Year?
Amarin (AMRN) Beats Earnings & Revenues Estimates in Q3
by Zacks Equity Research
Amarin beats estimates for both earnings and revenues in the third quarter of 2019. Shares up.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.
Amarin (AMRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $16.42 in the latest trading session, marking a +0.37% move from the prior day.
Is a Beat in Store for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Implied Volatility Surging for Amarin (AMRN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Is Amarin Corporation (AMRN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMRN) Outperforming Other Medical Stocks This Year?
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
by Zacks Equity Research
Key highlights of the past week include collaborations, and other regulatory and pipeline news.